Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are pleased to announce NEXSTELLIS ® (14.2 mg of estetrol and 3 mg drospirenone tablets), the first-of-its-kind oral contraceptive with a novel estrogen, is now available in Australia.
NEXTSTELLIS® contraceptive was approved by the Therapeutic Goods Administration (TGA) in November 2021 and is the first and only pill containing the new low impact1 estrogen, estetrol (E4), and a progestin, drospirenone (DRSP). E4 is a natural estrogen produced by the human body during pregnancy and in NEXTSTELLIS® , E4 is derived from a plant source. NEXTSTELLIS® will compete in the Australian combined (estrogen plus progestin) oral contraceptive market which is valued at A$ 60 million (circa EUR 40 million)2 . Combined oral contraceptives continue to be the most common method of contraception with nearly 1 million Australian women using them.
Mayne Pharma’s CEO Mr Scott Richards said: “We are delighted to introduce NEXTSTELLIS® contraceptive to the Australian market. NEXTSTELLIS® offers an effective, safe, and well-tolerated contraceptive pill with predictable cycle control and has demonstrated low impact on certain parts of the body. The launch will be supported by an expanded national GP/specialist sales team that are now educating healthcare professionals on the unique characteristics of E4.”
Mithra’s CEO Mr Leon Van Rompay said: “NEXTSTELLIS® unlocks a new era in contraception offering women and their healthcare providers a next generation birth control pill. Every woman’s body responds differently to contraceptive hormones and having a new estrogen available – E4 – opens up the possibility that more women will be able to find a combination that suits them. Mithra is excited to see the commercialisation of NEXTSTELLIS® contraceptive on a third continent.”